Loading clinical trials...
Loading clinical trials...
A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide B and Semaglutide D Administered sc
Conditions
Interventions
Semaglutide (administered by DV3396 pen)
Semaglutide (administered by PDS290 pen)
Locations
1
Netherlands
Novo Nordisk Investigational Site
Groningen, Netherlands
Start Date
October 28, 2019
Primary Completion Date
January 4, 2020
Completion Date
January 4, 2020
Last Updated
January 20, 2021
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions